Skip to main content
SpringerLink
Log in

Modeling Human Leukemia Using Immune-Compromised Mice

  • Chapter
  • First Online:
Mouse Models of Human Blood Cancers

  • 585 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bosma, G.C., Custer, R.P. & Bosma, M.J. A severe combined immunodeficiency mutation in the mouse. Nature 301, 527–530 (1983).

    Article  PubMed  CAS  Google Scholar 

  2. Mombaerts, P. et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869–877 (1992).

    Article  PubMed  CAS  Google Scholar 

  3. Shinkai, Y. et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855–867 (1992).

    Article  PubMed  CAS  Google Scholar 

  4. Shultz, L.D. et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 154, 180–191 (1995).

    PubMed  CAS  Google Scholar 

  5. Shultz, L.D. et al. NOD/LtSz-Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. J Immunol 164, 2496–2507 (2000).

    PubMed  CAS  Google Scholar 

  6. Shultz, L.D. et al. NOD/LtSz-Rag1nullPfpnull mice: a new model system with increased levels of human peripheral leukocyte and hematopoietic stem-cell engraftment. Transplantation 76, 1036–1042 (2003).

    Article  PubMed  Google Scholar 

  7. Christianson, S.W. et al. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J Immunol 158, 3578–3586 (1997).

    PubMed  CAS  Google Scholar 

  8. Cao, X. et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2, 223–238 (1995).

    Article  PubMed  CAS  Google Scholar 

  9. Sugamura, K. et al. The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 14, 179–205 (1996).

    Article  PubMed  CAS  Google Scholar 

  10. Ito, M. et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100, 3175–3182 (2002).

    Article  PubMed  CAS  Google Scholar 

  11. Shultz, L.D. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174, 6477–6489 (2005).

    PubMed  CAS  Google Scholar 

  12. Ishikawa, F. et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106, 1565–1573 (2005).

    Article  PubMed  CAS  Google Scholar 

  13. Honma, Y., Ishii, Y., Sassa, T. & Asahi, K. Treatment of human promyelocytic leukemia in the SCID mouse model with cotylenin A, an inducer of myelomonocytic differentiation of leukemia cells. Leuk Res 27, 1019–1025 (2003).

    Article  PubMed  CAS  Google Scholar 

  14. Kiser, M. et al. Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. Leukemia 15, 814–818 (2001).

    Article  PubMed  CAS  Google Scholar 

  15. Pirruccello, S.J. et al. OMA-AML-1: a leukemic myeloid cell line with CD34+ progenitor and CD15+ spontaneously differentiating cell compartments. Blood 80, 1026–1032 (1992).

    PubMed  CAS  Google Scholar 

  16. Terpstra, W. et al. Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice. Leukemia 9, 1573–1577 (1995).

    PubMed  CAS  Google Scholar 

  17. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).

    Article  PubMed  CAS  Google Scholar 

  18. Ailles, L.E., Gerhard, B., Kawagoe, H. & Hogge, D.E. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 94, 1761–1772 (1999).

    PubMed  CAS  Google Scholar 

  19. Pearce, D.J. et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107, 1166–1173 (2006).

    Article  PubMed  CAS  Google Scholar 

  20. Lumkul, R. et al. Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia 16, 1818–1826 (2002).

    Article  PubMed  CAS  Google Scholar 

  21. Yalcintepe, L., Frankel, A.E. & Hogge, D.E. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 108, 3530–3537 (2006).

    Article  PubMed  CAS  Google Scholar 

  22. Feuring-Buske, M. et al. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17, 760–763 (2003).

    Article  PubMed  CAS  Google Scholar 

  23. Ishikawa, fF. et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone marrow endosteal region. Nature Biotechnology 25, 1315–1321 (2007).

    Article  PubMed  CAS  Google Scholar 

  24. Ninomiya, M. et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 21, 136–142 (2007).

    Article  PubMed  CAS  Google Scholar 

  25. Liem, N.L. et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103, 3905–3914 (2004).

    Article  PubMed  CAS  Google Scholar 

  26. Nijmeijer, B.A. et al. Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Experimental Hematology 29, 322–329 (2001).

    Article  PubMed  CAS  Google Scholar 

  27. Schimmel, K.J., Nijmeijer, B.A., van Schie, M.L., Falkenburg, J.H. & Guchelaar, H.J. Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia. Leuk Res (2007).

    Google Scholar 

  28. Nijmeijer, B.A., van Schie, M.L., Verzaal, P., Willemze, R. & Falkenburg, J.H. Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia. Exp Hematol 33, 1172–1181 (2005).

    Article  PubMed  CAS  Google Scholar 

  29. Nijmeijer, B.A., Willemze, R. & Falkenburg, J.H. An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice. Blood 100, 654–660 (2002).

    Article  PubMed  CAS  Google Scholar 

  30. Jamieson, C.H. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351, 657–667 (2004).

    Article  PubMed  CAS  Google Scholar 

  31. Jaiswal, S. et al. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci U S A 100, 10002–10007 (2003).

    Article  PubMed  CAS  Google Scholar 

  32. Hoyle, C.F. & Negrin, R.S. Engraftment of chronic myeloid leukemia in SCID mice. Hematol Oncol 16, 87–100 (1998).

    Article  PubMed  CAS  Google Scholar 

  33. Namikawa, R., Ueda, R. & Kyoizumi, S. Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood 82, 2526–2536 (1993).

    PubMed  CAS  Google Scholar 

  34. Sawyers, C.L., Gishizky, M.L., Quan, S., Golde, D.W. & Witte, O.N. Propagation of human blastic myeloid leukemias in the SCID mouse. Blood 79, 2089–2098 (1992).

    PubMed  CAS  Google Scholar 

  35. Sirard, C. et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood 87, 1539–1548 (1996).

    PubMed  CAS  Google Scholar 

  36. Beran, M. et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 53, 3603–3610 (1993).

    PubMed  CAS  Google Scholar 

  37. Skorski, T., Nieborowska-Skorska, M. & Calabretta, B. A model of Ph' positive chronic myeloid leukemia-blast crisis cell line growth in immunodeficient SCID mice. Folia Histochem Cytobiol 30, 91–96 (1992).

    PubMed  CAS  Google Scholar 

  38. Dazzi, F. et al. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. Blood 92, 1390–1396 (1998).

    PubMed  CAS  Google Scholar 

  39. Lewis, I.D., McDiarmid, L.A., Samels, L.M., To, L.B. & Hughes, T.P. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood 91, 630–640 (1998).

    PubMed  CAS  Google Scholar 

  40. Verstegen, M.M., Cornelissen, J.J., Terpstra, W., Wagemaker, G. & Wognum, A.W. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice. Leukemia 13, 618–628 (1999).

    Article  PubMed  CAS  Google Scholar 

  41. Wang, J.C. et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 91, 2406–2414 (1998).

    PubMed  CAS  Google Scholar 

  42. Eisterer, W. et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 19, 435–441 (2005).

    Article  PubMed  CAS  Google Scholar 

  43. Carlo-Stella, C. et al. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Exp Hematol 34, 721–727 (2006).

    Article  PubMed  CAS  Google Scholar 

  44. Ito, K. et al. 1′-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res 65, 4417–4424 (2005).

    Article  PubMed  CAS  Google Scholar 

  45. Mitsiades, C.S. et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 63, 6689–6696 (2003).

    PubMed  CAS  Google Scholar 

  46. Tassone, P. et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 106, 713–716 (2005).

    Article  PubMed  CAS  Google Scholar 

  47. Yaccoby, S., Barlogie, B. & Epstein, J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92, 2908–2913 (1998).

    PubMed  CAS  Google Scholar 

  48. Dewan, M.Z. et al. Prompt tumor formation and maintenance of constitutive NF-kappaB activity of multiple myeloma cells in NOD/SCID/gammacnull mice. Cancer Sci 95, 564–568 (2004).

    Article  PubMed  CAS  Google Scholar 

  49. Bonnet, D. & Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3, 730–737 (1997).

    Article  PubMed  CAS  Google Scholar 

  50. Feuring-Buske, M. & Hogge, D.E. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(–) progenitor cells from patients with acute myeloid leukemia. Blood 97, 3882–3889 (2001).

    Article  PubMed  CAS  Google Scholar 

  51. Sperr, W.R. et al. Human leukaemic stem cells: a novel target of therapy. European journal of clinical investigation 34 Suppl 2, 31–40 (2004).

    Article  PubMed  CAS  Google Scholar 

  52. Buccisano, F. et al. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br J Haematol 125, 203–212 (2004).

    Article  PubMed  CAS  Google Scholar 

  53. Jordan, C.T. et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777–1784 (2000).

    Article  PubMed  CAS  Google Scholar 

  54. Hosen, N. et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A 104, 11008–11013 (2007).

    Article  PubMed  CAS  Google Scholar 

  55. Guzman, M.L. et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105, 4163–4169 (2005).

    Article  PubMed  CAS  Google Scholar 

  56. Guzman, M.L. et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A 99, 16220–16225 (2002).

    Article  PubMed  CAS  Google Scholar 

  57. Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F. & Dick, J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12, 1167–1174 (2006).

    Article  PubMed  Google Scholar 

  58. Krause, D.S., Lazarides, K., von Andrian, U.H. & Van Etten, R.A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 12, 1175–1180 (2006).

    Article  PubMed  CAS  Google Scholar 

  59. Dar, A., Kollet, O. & Lapidot, T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol 34, 967–975 (2006).

    Article  PubMed  CAS  Google Scholar 

  60. Tavor, S. et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 64, 2817–2824 (2004).

    Article  PubMed  CAS  Google Scholar 

  61. Hotfilder, M. et al. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res 65, 1442–1449 (2005).

    Article  PubMed  CAS  Google Scholar 

  62. Castor, A. et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 11, 630–637 (2005).

    Article  PubMed  CAS  Google Scholar 

  63. George, A.A. et al. Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood 97, 3925–3930 (2001).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Unit for Human Disease Models, RIKEN Research Center for Allergy and Immunology, Yokohama 230-0045, Japan

    Fumihiko Ishikawa

Authors
  1. Fumihiko Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yariko Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leonard D. Shultz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2008 Springer Science+Business Media, LLC

    About this chapter

    Cite this chapter

    Ishikawa, F., Saito, Y., Shultz, L.D. (2008). Modeling Human Leukemia Using Immune-Compromised Mice. In: Li, S. (eds) Mouse Models of Human Blood Cancers. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69132-9_5

    Download citation

    Publish with us

    Policies and ethics

    Search

    Navigation